Main extrahematologic and hematologic toxicities in the 39 patients treated with imatinib
| Toxicities . | Patients experiencing toxicities by grade . | ||
|---|---|---|---|
| 1–2 . | 3 . | 4 . | |
| Extrahematologic | |||
| Nausea | 7 (17%) | 0 | 0 |
| Diarrhea | 5 (12%) | 0 | 0 |
| Cramps | 14 (35%) | 1 (2%) | 1 (2%) |
| Muscle pain | 11 (28%) | 3 (7%) | 2 (5%) |
| Peripheral edema | 6 (15%) | 1 (2%) | 0 |
| Periorbital edema | 5 (12%) | 2 (5%) | 0 |
| Asthenia | 13 (33%) | 2 (5%) | 2 (5%) |
| Emesis | 2 (5%) | 0 | 0 |
| Abdominal pain | 5 (12%) | 0 | 0 |
| Rash | 2 (5%) | 0 | 0 |
| Kidney | 5 (12%) | 0 | 0 |
| Muscle weakness | 9 (23%) | 2 (5%) | 1 (2%) |
| Liver | 1 (2%) | 0 | 0 |
| Neuropathy | 1 (2%) | 0 | 0 |
| Weight gain | 2 (5%) | 0 | 0 |
| Heart failure | 2 (5%) | 0 | 0 |
| Bullous dermatitis | 0 | 0 | 1 (2%) |
| Hematologic | |||
| Anemia | 25 (64%) | 1 (2%) | 0 |
| Neutropenia | 6 (15%) | 0 | 0 |
| Thrombocytopenia | 4 (10%) | 1 (2%) | 0 |
| Toxicities . | Patients experiencing toxicities by grade . | ||
|---|---|---|---|
| 1–2 . | 3 . | 4 . | |
| Extrahematologic | |||
| Nausea | 7 (17%) | 0 | 0 |
| Diarrhea | 5 (12%) | 0 | 0 |
| Cramps | 14 (35%) | 1 (2%) | 1 (2%) |
| Muscle pain | 11 (28%) | 3 (7%) | 2 (5%) |
| Peripheral edema | 6 (15%) | 1 (2%) | 0 |
| Periorbital edema | 5 (12%) | 2 (5%) | 0 |
| Asthenia | 13 (33%) | 2 (5%) | 2 (5%) |
| Emesis | 2 (5%) | 0 | 0 |
| Abdominal pain | 5 (12%) | 0 | 0 |
| Rash | 2 (5%) | 0 | 0 |
| Kidney | 5 (12%) | 0 | 0 |
| Muscle weakness | 9 (23%) | 2 (5%) | 1 (2%) |
| Liver | 1 (2%) | 0 | 0 |
| Neuropathy | 1 (2%) | 0 | 0 |
| Weight gain | 2 (5%) | 0 | 0 |
| Heart failure | 2 (5%) | 0 | 0 |
| Bullous dermatitis | 0 | 0 | 1 (2%) |
| Hematologic | |||
| Anemia | 25 (64%) | 1 (2%) | 0 |
| Neutropenia | 6 (15%) | 0 | 0 |
| Thrombocytopenia | 4 (10%) | 1 (2%) | 0 |